Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (140) 140
science & technology (96) 96
female (91) 91
life sciences & biomedicine (91) 91
oncology (62) 62
male (61) 61
middle aged (58) 58
phosphoramide mustards - administration & dosage (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
phosphoramide mustards - therapeutic use (56) 56
animals (53) 53
biological and medical sciences (53) 53
medical sciences (51) 51
pharmacology. drug treatments (42) 42
adult (41) 41
aged (40) 40
antineoplastic agents (39) 39
mice (37) 37
phosphoramide mustards - pharmacology (37) 37
chemotherapy (33) 33
doxorubicin - administration & dosage (33) 33
pharmacology & pharmacy (33) 33
cisplatin - administration & dosage (30) 30
antineoplastic agents - therapeutic use (29) 29
phosphoramide mustards - adverse effects (29) 29
cancer (25) 25
neoplasms - drug therapy (25) 25
phosphoramide mustards - pharmacokinetics (25) 25
tumors (25) 25
cyclophosphamide - analogs & derivatives (23) 23
cyclophosphamide - therapeutic use (21) 21
nitroimidazoles - pharmacology (21) 21
cell line, tumor (20) 20
hypoxia (20) 20
ifosfamide - analogs & derivatives (19) 19
ovarian neoplasms - drug therapy (19) 19
nitroimidazoles - administration & dosage (18) 18
phosphoramide mustards - metabolism (18) 18
antineoplastic agents - pharmacology (17) 17
cyclophosphamide - administration & dosage (17) 17
xenograft model antitumor assays (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
cyclophosphamide (15) 15
doxorubicin - therapeutic use (15) 15
time factors (15) 15
combined modality therapy (14) 14
nitroimidazoles - therapeutic use (14) 14
research (14) 14
antineoplastic agents, alkylating - therapeutic use (13) 13
cell survival - drug effects (13) 13
clinical trials as topic (13) 13
neoplasm staging (13) 13
prodrugs - pharmacology (13) 13
treatment outcome (13) 13
adolescent (12) 12
breast neoplasms - drug therapy (12) 12
cisplatin - therapeutic use (12) 12
rats (12) 12
adenocarcinoma - drug therapy (11) 11
cyclophosphamide - pharmacokinetics (11) 11
doxorubicin - adverse effects (11) 11
glucose - analogs & derivatives (11) 11
ifosfamide - therapeutic use (11) 11
cell hypoxia (10) 10
kinetics (10) 10
leukemia l1210 - drug therapy (10) 10
pancreatic cancer (10) 10
pharmacology/toxicology (10) 10
phosphoramide mustard (10) 10
phosphoramide mustards - blood (10) 10
prodrugs - administration & dosage (10) 10
th-302 (10) 10
abridged index medicus (9) 9
aged, 80 and over (9) 9
antineoplastic agents - pharmacokinetics (9) 9
cyclophosphamide - adverse effects (9) 9
cyclophosphamide - metabolism (9) 9
cytotoxicity (9) 9
dose-response relationship, drug (9) 9
evofosfamide (9) 9
glufosfamide (9) 9
mice, nude (9) 9
pharmacokinetics (9) 9
research article (9) 9
sarcoma - drug therapy (9) 9
survival rate (9) 9
analysis (8) 8
antineoplastic agents, alkylating - pharmacology (8) 8
cancer research (8) 8
cancer therapies (8) 8
care and treatment (8) 8
cell hypoxia - drug effects (8) 8
cell proliferation - drug effects (8) 8
chemistry (8) 8
clinical trials (8) 8
drug evaluation (8) 8
drug therapy (8) 8
half-life (8) 8
hematology (8) 8
hypoxia-activated prodrug (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [F-18]HX4 Hypoxia PET Imaging
by Peeters, Sarah G. J. A and Zegers, Catharina M. L and Biemans, Rianne and Lieuwes, Natasja G and van Stiphout, Ruud G. P. M and Yaromina, Ala and Sun, Jessica D and Hart, Charles P and Windhorst, Albert D and van Elmpt, Wouter and Dubois, Ludwig J and Lambin, Philippe
Clinical cancer research, ISSN 1078-0432, 07/2015, Volume 21, Issue 13, pp. 2984 - 2992
Life Sciences & Biomedicine | Oncology | Science & Technology | Nitroimidazoles - pharmacology | Phosphoramide Mustards - pharmacology | Rats | Treatment Outcome | Antineoplastic Agents - therapeutic use | Lung Neoplasms - therapy | Positron-Emission Tomography | Chemoradiotherapy | Cell Hypoxia | Xenograft Model Antitumor Assays | Carcinoma, Non-Small-Cell Lung - therapy | Animals | Imidazoles | Nitroimidazoles - therapeutic use | Phosphoramide Mustards - therapeutic use | Triazoles | Lung Neoplasms - diagnostic imaging | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Radiopharmaceuticals | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies
by Weiss, Glen J and Infante, Jeffrey R and Chiorean, E. Gabriela and Borad, Mitesh J and Bendell, Johanna C and Molina, Julian R and Tibes, Raoul and Ramanathan, Ramesh K and Lewandowski, Karen and Jones, Suzanne F and Lacouture, Mario E and Langmuir, Virginia K and Lee, Hank and Kroll, Stew and Burris III, Howard A
Clinical cancer research, ISSN 1078-0432, 05/2011, Volume 17, Issue 9, pp. 2997 - 3004
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Neoplasms - metabolism | Prodrugs - administration & dosage | Cell Hypoxia - physiology | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Nitroimidazoles - adverse effects | Nitroimidazoles - therapeutic use | Phosphoramide Mustards - pharmacokinetics | Phosphoramide Mustards - therapeutic use | Antineoplastic Agents - adverse effects | Phosphoramide Mustards - administration & dosage | Phosphoramide Mustards - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Nitroimidazoles - pharmacokinetics | Nitroimidazoles - administration & dosage | Cell Hypoxia - drug effects | Disease Progression | Neoplasms - drug therapy | Prodrugs - adverse effects | Maximum Tolerated Dose | Prodrugs - pharmacokinetics | Models, Biological | Aged | Prodrugs - therapeutic use | Neoplasms - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
by Tap, William D and Papai, Zsuzsanna and Van Tine, Brian A and Attia, Steven and Ganjoo, Kristen N and Jones, Robin L and Schuetze, Scott and Reed, Damon and Chawla, Sant P and Riedel, Richard F and Krarup-Hansen, Anders and Toulmonde, Maud and Ray-Coquard, Isabelle and Hohenberger, Peter and Grignani, Giovanni and Cranmer, Lee D and Okuno, Scott and Agulnik, Mark and Read, William and Ryan, Christopher W and Alcindor, Thierry and del Muro, Xavier F Garcia and Budd, G Thomas and Tawbi, Hussein and Pearce, Tillman and Kroll, Stew and Reinke, Denise K and Schöffski, Patrick
The lancet oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1089 - 1103
Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Phosphoramide Mustards - blood | Soft Tissue Neoplasms - drug therapy | Male | Nitroimidazoles - blood | Nitroimidazoles - adverse effects | Soft Tissue Neoplasms - surgery | Exanthema - chemically induced | Phosphoramide Mustards - administration & dosage | Phosphoramide Mustards - adverse effects | Female | Doxorubicin - administration & dosage | Nitroimidazoles - administration & dosage | Drug Eruptions - etiology | Hematologic Diseases - chemically induced | Survival Rate | Sarcoma - drug therapy | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sarcoma - surgery | Stomatitis - chemically induced | Aged | Doxorubicin - adverse effects | Anthracyclines | Product development | Metastasis | Sarcoma | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/ Refractory Multiple Myeloma
by Laubach, Jacob P and Liu, Chia-Jen and Raje, Noopur S and Yee, Andrew J and Armand, Philippe and Schlossman, Robert L and Rosenblatt, Jacalyn and Hedlund, Jacquelyn and Martin, Michael and Reynolds, Craig and Shain, Kenneth H and Zackon, Ira and Stampleman, Laura and Henrick, Patrick and Rivotto, Bradley and Hornburg, Kalvis T.V and Dumke, Henry J and Chuma, Stacey and Savell, Alexandra and Handisides, Damian R and Kroll, Stew and Anderson, Kenneth C and Richardson, Paul G and Ghobrial, Irene M
Clinical cancer research, ISSN 1078-0432, 01/2019, Volume 25, Issue 2, pp. 478 - 486
Life Sciences & Biomedicine | Oncology | Science & Technology | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Nitroimidazoles - adverse effects | Multiple Myeloma - drug therapy | Nitroimidazoles - therapeutic use | Phosphoramide Mustards - therapeutic use | Phosphoramide Mustards - administration & dosage | Phosphoramide Mustards - adverse effects | Aged, 80 and over | Female | Nitroimidazoles - administration & dosage | Multiple Myeloma - diagnosis | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Treatment Outcome | Disease Progression | Retreatment | Multiple Myeloma - etiology | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text PICASSO III: A phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma
by Ryan, Christopher W and Merimsky, Ofer and Agulnik, Mark and Blay, Jean-Yves and Schuetze, Scott M and Van Tine, Brian A and Jones, Robin L and Elias, Anthony D and Choy, Edwin and Alcindor, Thierry and Keedy, Vicki L and Reed, Damon R and Taub, Robert N and Italiano, Antoine and Del Muro, Xavier Garcia and Judson, Ian R and Buck, Jill Y and Lebel, Francois and Lewis, Jonathan J and Maki, Robert G and Schöffski, Patrick
Journal of clinical oncology, ISSN 0732-183X, 11/2016, Volume 34, Issue 32, pp. 3898 - 3905
Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Sarcoma - drug therapy | Sarcoma - pathology | Disease-Free Survival | Neoplasm Metastasis | Neoplasm Grading | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Phosphoramide Mustards - administration & dosage | Phosphoramide Mustards - adverse effects | Placebos | Female | Aged | Doxorubicin - adverse effects | Doxorubicin - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models
by Sun, Jessica D and Liu, Qian and Ahluwalia, Dharmendra and Ferraro, Damien J and Wang, Yan and Jung, Don and Matteucci, Mark D and Hart, Charles P
Cancer biology & therapy, ISSN 1538-4047, 04/2016, Volume 17, Issue 4, pp. 371 - 380
non-small cell lung cancer | hypoxia | ifosfamide | Evofosfamide | hypoxia-activated prodrug | xenograft | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Ifosfamide - pharmacology | Lung Neoplasms - drug therapy | Ifosfamide - therapeutic use | Nitroimidazoles - pharmacology | Phosphoramide Mustards - pharmacology | Lung Neoplasms - mortality | Humans | Lung Neoplasms - pathology | Carcinoma, Non-Small-Cell Lung - mortality | Xenograft Model Antitumor Assays | Animals | Nitroimidazoles - therapeutic use | Ifosfamide - administration & dosage | Phosphoramide Mustards - therapeutic use | Phosphoramide Mustards - administration & dosage | Mice | Prodrugs - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Prodrugs - pharmacology | Nitroimidazoles - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Glufosfamide as a new oxazaphosphorine anticancer agent
by Mazur, Lidia and Opydo-Chanek, Małgorzata and Stojak, Marta
Anti-cancer drugs, ISSN 0959-4973, 07/2011, Volume 22, Issue 6, pp. 488 - 493
alkylating drugs | cancer therapy | novel anticancer agent | preclinical studies and clinical trials | glufosfamide | β-D-glucose-isophosphoramide mustard | D-19575 | new therapeutic strategy | oxazaphosphorines | Pharmacology & Pharmacy | Oncology | Life Sciences & Biomedicine | Science & Technology | Phosphoramide Mustards - pharmacology | Humans | Glucose - analogs & derivatives | Antineoplastic Agents, Alkylating - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Phosphoramide Mustards - pharmacokinetics | Phosphoramide Mustards - therapeutic use | Drug Design | Phosphoramide Mustards - adverse effects | Cell Death - drug effects | Ifosfamide - pharmacokinetics | Cell Survival - drug effects | Glucose - adverse effects | Ifosfamide - pharmacology | Ifosfamide - therapeutic use | Ifosfamide - adverse effects | Antineoplastic Agents, Alkylating - pharmacokinetics | Glucose - pharmacology | Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Glucose - pharmacokinetics | Cell Line, Tumor | Glucose - therapeutic use | Ifosfamide - analogs & derivatives | Neoplasms - pathology | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
by Ganjoo, Kristen N and Cranmer, Lee D and Butrynski, James E and Rushing, Daniel and Adkins, Douglas and Okuno, Scott H and Lorente, Gustavo and Kroll, Stew and Langmuir, Virginia K and Chawla, Sant P
Oncology, ISSN 0030-2414, 06/2011, Volume 80, Issue 1-2, pp. 50 - 56
Clinical Study | Soft tissue sarcoma | Hypoxia-activated prodrug | Phase I clinical trial | TH-302 | Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Biological and medical sciences | Medical sciences | Dermatology | Tumors | Doxorubicin - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Young Adult | Nitroimidazoles - adverse effects | Nitroimidazoles - therapeutic use | Phosphoramide Mustards - pharmacokinetics | Phosphoramide Mustards - therapeutic use | Doxorubicin - analogs & derivatives | Phosphoramide Mustards - adverse effects | Aged, 80 and over | Adult | Female | Neoadjuvant Therapy | Doxorubicin - metabolism | Neutropenia - chemically induced | Nitroimidazoles - pharmacokinetics | Drug Eruptions | Abscess - etiology | Anemia - chemically induced | Treatment Outcome | Granulocyte Colony-Stimulating Factor - therapeutic use | Sarcoma - drug therapy | Doxorubicin - pharmacokinetics | Neutropenia - drug therapy | Cellulitis - chemically induced | Disease-Free Survival | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sarcoma - surgery | Stomatitis - chemically induced | Aged | Doxorubicin - adverse effects | Lymphopenia - chemically induced | Drug therapy | Pharmacology | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Short-term exposure of human ovarian follicles to cyclophosphamide metabolites seems to promote follicular activation in vitro
by Lande, Yechezkel and Fisch, Benjamin and Tsur, Abraham and Farhi, Jacob and Prag-Rosenberg, Roni and Ben-Haroush, Avi and Kessler-Icekson, Gania and Zahalka, Muayad A and Ludeman, Susan M and Abir, Ronit
Reproductive biomedicine online, ISSN 1472-6483, 2016, Volume 34, Issue 1, pp. 104 - 114
Obstetrics and Gynecology | 4-hydroperoxycyclophamide (4hc) | the ‘burnout’ theory | 4-hydroxycyclophosphamide(4-OHC) | cyclophosphamide metabolites | in vitro | human primordial follicles | phosphoramide mustard (PM) | developing follicles | Life Sciences & Biomedicine | Obstetrics & Gynecology | Reproductive Biology | Science & Technology | Estradiol - metabolism | Cyclophosphamide - analogs & derivatives | Humans | Immunosuppressive Agents - therapeutic use | Ki-67 Antigen - metabolism | Embryo Culture Techniques | Cyclophosphamide - therapeutic use | Freezing | Ovarian Follicle - drug effects | Phosphoramide Mustards - therapeutic use | Time Factors | Anti-Mullerian Hormone - therapeutic use | Cryopreservation | Culture Media | Adolescent | Female | Child | Ovary - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Activity of the hypoxia‐activated pro‐drug TH‐302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy
by Saggar, Jasdeep K and Tannock, Ian F
International journal of cancer, ISSN 0020-7136, 06/2014, Volume 134, Issue 11, pp. 2726 - 2734
drug distribution | pharmacodynamic markers | TH‐302 | drug penetration | tumor microenvironment | hypoxia‐activated pro‐drug | TH-302 | hypoxia-activated pro-drug | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Tumors | Prostatic Neoplasms - blood supply | Prostatic Neoplasms - pathology | Cell Hypoxia - drug effects | Biomarkers, Tumor - analysis | Humans | Male | Breast Neoplasms - blood supply | Breast Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Mice, Nude | Phosphoramide Mustards - administration & dosage | Female | Mice | Prodrugs - therapeutic use | Tumor Cells, Cultured | Prostatic Neoplasms - drug therapy | Doxorubicin - administration & dosage | Nitroimidazoles - administration & dosage | Anthracyclines | Chemotherapy | Health aspects | Cancer | Hypoxia | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
by Meng, Fanying and Bhupathi, Deepthi and Sun, Jessica D and Liu, Qian and Ahluwalia, Dharmendra and Wang, Yan and Matteucci, Mark D and Hart, Charles P
BMC cancer, ISSN 1471-2407, 05/2015, Volume 15, Issue 1, pp. 422 - 422
Hypoxia-activated prodrug | Xenograft models | DNA damage | in vivo anti-tumor activity | in vitro cytotoxicity | Hypoxia | Chk1 inhibitor | DNA repair | Cancer | In vivo anti-tumor activity | In vitro cytotoxicity | Life Sciences & Biomedicine | Oncology | Science & Technology | Protein Kinases - metabolism | Thiophenes - therapeutic use | Phosphorylation | Phosphoramide Mustards - pharmacology | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Agents - therapeutic use | Phosphoproteins - metabolism | Tumor Suppressor Protein p53 - genetics | CDC2 Protein Kinase - metabolism | Nitroimidazoles - therapeutic use | Phosphoramide Mustards - therapeutic use | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | DNA Damage - drug effects | Rad51 Recombinase - metabolism | Cell Survival - drug effects | Nitroimidazoles - pharmacology | Thiophenes - pharmacology | Tumor Suppressor Protein p53 - deficiency | HT29 Cells | Urea - therapeutic use | Animals | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | Mice, Nude | Protein Kinase Inhibitors - therapeutic use | Checkpoint Kinase 1 | Mice | Protein Kinase Inhibitors - pharmacology | Histones - metabolism | Mutation | Urea - pharmacology | Tumor proteins | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
by Yoon, C and Lee, H.-J and Park, D.J and Lee, Y.-J and Tap, W.D and Eisinger-Mathason, T.S.K and Hart, C.P and Choy, E and Simon, M.C and Yoon, S.S
British journal of cancer, ISSN 0007-0920, 06/2015, Volume 113, Issue 1, pp. 46 - 56
hypoxia | sarcoma | VEGF-A | radiation | Life Sciences & Biomedicine | Oncology | Science & Technology | Activation, Metabolic | Humans | Male | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Sarcoma - drug therapy | Xenograft Model Antitumor Assays | Animals | Nitroimidazoles - therapeutic use | Phosphoramide Mustards - pharmacokinetics | Phosphoramide Mustards - therapeutic use | Antineoplastic Agents - pharmacokinetics | Mice | Mice, Inbred BALB C | Hypoxia-Inducible Factor 1, alpha Subunit - physiology | Sarcoma - radiotherapy | Nitroimidazoles - pharmacokinetics | Index Medicus | Translational Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights